Algatech invests in Supreme Health

ISRAEL-BASED Algatechnologies, Ltd increased its shares in Supreme Health, Ltd to supply algae-based products to markets in China and the rest of Asia Pacific.

The new deal enables Supreme Health to draw on Algatech’s expertise and microalgae cultivation technologies for the production of its natural astaxanthin from a unique strain of the microalgae, Haematococcus pluvialis.

Supreme Health, led by CEO Kerry Paul, has marketing channels in China, New Zealand, and Australia, and will focus on marketing microalgae ingredients and astaxanthin-based products to food, dietary supplement, and cosmetic industries throughout Asia-Pacific, particularly in China. 

Algatech, located in the Arava desert in Israel, specialises in the commercial cultivation of microalgae. Its natural astaxanthin is marketed in 35 countries under its AstaPure® brand.

“This investment is in line with our core strategy to expand the potential of microalgae derived products, especially natural astaxanthin which is our key ingredient,” says Hagai Stadler, CEO of Algatech. “Collaborating with Supreme allows us to increase our service of Asia-Pacific, especially in China. We identified a rapidly growing interest in those regions for quality astaxanthin and other quality algae-delivered products.”

“We believe that the synergy between companies, together with Mr. Paul’s wide experience and proven track record, will help Supreme to become a major player in the global market,” contributes Algatech chairman Ed Hofland, who will also serve as Supreme’s president.

Securing this partnership with Algatechnologies places us at the forefront of micro-algal production globally, and help us to build a global sales and distribution capabilities”, says Paul. “Products derived from microalgae produced in a sustainable system are on-trend and supported by strong scientific research. The key bioactives in microalgae show increased efficacy in higher concentrations.”